CAR-T cancer therapy under scrutiny: could it trigger new tumors?
NCT ID NCT07378969
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines stored tumor and blood samples from 30 patients who developed a secondary T-cell cancer after receiving the CAR-T therapy tisagenlecleucel. Researchers will test whether the therapy's genetic material is present in the tumor cells, which could suggest a role in cancer development. The goal is to better understand any potential safety risk, not to offer a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If this study finds a link, it could help improve safety monitoring for CAR-T therapies and guide future treatment decisions.
- What could go wrong
- This is a small, observational study with only 30 participants. It cannot prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY MALIGNANCIES OF T-CELL ORIGIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
ACTIVE_NOT_RECRUITINGKurume, Fukuoka, 830-8543, Japan
-
Novartis Investigative Site
RECRUITINGOsaka, Osaka, 5418567, Japan
-
Novartis Investigative Site
RECRUITINGSuita, Osaka, 565-0871, Japan
-
Novartis Investigative Site
RECRUITINGBunkyo Ku, Tokyo, 1138677, Japan